Perspective Therapeutics (CATX) Earnings Date & Reports

Key Takeaways

• Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per basic and diluted share, compared with a net loss of $26.0 million, or $0.35 per share, in the same period a year earlier.
• The company's reported loss per share of $0.27 came in below the consensus estimate of roughly $0.24, while grant revenue of $20,000 also fell short of analyst expectations.
• Research and development (R&D) expenses rose to $26.1 million from $20.3 million, reflecting increased investment across the company's three clinical-stage oncology programs.
• Cash, cash equivalents, and short-term investments totaled approximately $202 million as of September 30, 2026, which management expects to fund planned clinical milestones and operational investments into 2028.
• Key pipeline updates included completion of Cohort 4 enrollment in the VMT-α-NET neuroendocrine tumor program and U.S. Food and Drug Administration (FDA) Fast Track Designation for PSV359.
• For more information about this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• To discover data-driven trade ideas and market signals, explore Trending AI Robots.

Earnings Context and Why It Matters

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha therapies (TAT) that use the isotope Lead-212 (212Pb) to deliver radiation directly to cancer cells. Because the company has not yet commercialized a product, its quarterly results are driven less by revenue and more by two factors investors watch closely: the pace of spending on clinical development and, crucially, pipeline progress. This report matters because it offers a read on the company's cash runway and the momentum of its lead programs heading into pivotal 2027 data readouts. For a pre-revenue biotech, guidance on timelines and regulatory milestones often moves the stock more than the income statement itself.

Reported Results

For the third quarter ended September 30, 2026, Perspective Therapeutics reported grant revenue of $20,000, down from $209,000 in the prior-year period. The company posted a net loss of $32.4 million, or $0.27 per basic and diluted share, compared with a net loss of $26.0 million, or $0.35 per share, a year earlier. The loss per share of $0.27 was slightly wider than the consensus estimate of about $0.24, while revenue also missed expectations. Total operating expenses rose to $34.3 million from $28.1 million, driven primarily by higher R&D spending, which increased to $26.1 million from $20.3 million. General and administrative (G&A) expenses were $8.3 million, up from $7.7 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your research workflow.

Market Reaction and Investor Sentiment

The market reacted negatively to the third-quarter report, with shares trading sharply lower in the session following the November 9, 2026 announcement. For a development-stage biotech, a modest miss on a non-GAAP-style loss-per-share metric is often secondary to clinical news, but the combination of a wider-than-expected loss and a steep year-over-year decline in already-minimal grant revenue appeared to weigh on sentiment. Investors are balancing near-term expense growth against the company's stated runway into 2028 and a series of potentially transformative data readouts expected in 2027. The stock's reaction underscores how sensitive pre-revenue biotech names remain to any signal around capital efficiency and program timing.

Forward Outlook and Key Factors to Monitor

Looking ahead, the investment thesis for Perspective Therapeutics will hinge on execution across its three oncology franchises rather than on quarterly financial figures. Management is targeting an end-of-Phase 2 (EOP2) meeting with the FDA in the first quarter of 2027 for the lead program bamzireotide navoxetan (VMT-α-NET) in neuroendocrine tumors, a regulatory step that could define the path toward a registration-enabling study.

Investors should monitor the timing and content of upcoming data presentations, including updates from the VMT-α-NET cohorts, the lapemelanotide zapixetar (VMT01) melanoma program, and the PSV359 program in solid tumors. The October 2026 Fast Track Designation for PSV359 in FAP-positive solitary fibrous tumors and a September 2026 clinical collaboration with Merck to evaluate PSV359 in combination with Keytruda (pembrolizumab) add catalysts worth watching.

On the operational side, completion of the Chicago metro manufacturing site in early 2027 will be an important milestone for the company's Lead-212 supply chain and long-term scalability. Finally, cost discipline will remain in focus, as rising R&D spending must stay aligned with the company's stated cash runway, which management currently expects to support operations into 2028.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations